Rheinmetall's Danish Decoy Deal and German Field Hospital Order Keep the Order Book Humming

Rheinmetall's steady contract flow offsets naval setbacks, with record backlog and upcoming Boxer decision boosting outlook.

The defense contractor's steady drip of mid-sized contracts is doing what its flagship programs currently cannot: keeping the pipeline full. Rheinmetall has secured an order from the Danish armed forces for its MASS (Multi Ammunition Softkill System) decoy launchers, fitted to the Absalon- and Iver Huitfeldt-class frigates as well as the Royal Danish Naval Academy. Deliveries are slated to begin in the fourth quarter of 2027, with the order already booked in the second quarter of 2026.

The Danish deal is hardly a one-off. Rheinmetall says more than 400 of the launchers are now deployed worldwide, shielding vessels across 18 navies. Each individual contract may look modest against the group's headline figures, but collectively they have pushed the order backlog to a record €80.5 billion at the end of the second quarter. Management is targeting a backlog of €100–120 billion by the end of 2026 — a goal that looks increasingly attainable given the current cadence of new business.

A Medical Order With a Wider Margin

Fresh off the Danish announcement, Rheinmetall also confirmed an additional Bundeswehr order for mobile field hospitals, valued at over €500 million gross. That extends an earlier contract from 149 to 165 systems, bringing the total value of the medical equipment program past €600 million gross. Production is due to start in the first quarter of 2027.

The timing is telling. Rheinmetall is still absorbing the shock of a lowered full-year sales forecast — now pegged at €13.7–14.2 billion — after the German government halted a delayed frigate program. The company quantified the hit at €300 million. While the naval setback weighs on the top line, the land systems and medical divisions are clearly filling the gap: first-half revenue came in at €5.227 billion with operating profit of €333 million.

Eyes on the Boxer Decision

Investors, however, are looking past these incremental wins toward the winter's bigger catalysts. On December 9, the Bundestag is scheduled to debate the Arminius Boxer order — a fixed-order volume of roughly €25 billion, of which Rheinmetall's share would be around €12.4 billion. Contract signing is expected days later, with final negotiations set for the second week of September. A potential service contract for the Boxer fleet, worth an estimated €2 billion to Rheinmetall, could follow in January 2027.

Across the Atlantic, the Lockheed Martin partnership on ATACMS production at Unterlüss is progressing, though more slowly than some had hoped. A memorandum of understanding was signed in July, production ramp-up is planned for 2027, and first revenues are not expected until 2028. CEO Armin Papperger has been candid about the timeline: rebuilding US ammunition stocks cannot be accomplished within two years.

Share Price Still Digging Out

The stock traded at €1,211.80 on Tuesday, roughly 10 percent above its 50-day moving average. That marks a 3.1 percent gain on the week and a 23 percent rebound over the past month — a recovery from the sharp sell-off triggered by the August guidance cut. Yet the shares remain 40 percent below their 52-week high of €2,007, hit in early October, and are down 22 percent year-to-date.

Analysts have largely held their ground despite the reduced outlook. Jefferies lifted its price target to €1,350 from €1,300 on Monday, maintaining a Buy rating. JPMorgan reaffirmed Neutral with a €1,350 target the same day. The range of targets suggests genuine disagreement over how quickly the naval business can recover.

The Danish and German orders won't move the needle on their own. But they send a clear signal that the operational engine keeps running even as flagship programs stumble — and with the Boxer decision looming in December, the winter months will determine whether the backlog story finally translates into share price momentum.